Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 18, 2025Journal of Medicinal Chemistry

Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects

View Full Paper
Ask AI
Bookmark
Share

Authors

SWShuang WangYLYun LiuZYZhiming Yan

Discussion

Loading...

Member takes

Overview

Research demonstrates innovative triple receptor activation shows similar efficacy in weight loss and glycemic control in obesity and diabetes.

Key Points

  • Triple activation of GLP-1R, GCGR, and GIPR offers a promising treatment for obesity and diabetes, enhancing metabolic effects and weight loss.
  • The developed triagonists, particularly xGLP/GCG/GIP-32, exhibit superior weight reduction and metabolic profiles compared to tirzepatide.
  • Methodologies like molecular dynamics simulations, sequence analysis, and amino acid optimization were pivotal in designing effective receptor agonists.
  • This research supports exploring varied receptor activation ratios, suggesting biased agonism can be beneficial in therapeutic strategies.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68d462ca31b076d99fa620d5https://doi.org/10.1021/acs.jmedchem.5c02032
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mechanisms of Glucagon Receptor Agonism and GLP-1/Glucagon/GIP Receptor Triple Agonism for Treatment of Diabetes and Obesity2024 · 1 citations
  2. 2Design and biological evaluation of triagonist GLP-1R/GCGR/GIPR peptides as potential therapeutic agents for diabetes and obesity2026
  3. 3A Sequential Dual <scp>GLP</scp> ‐ <scp>1R</scp> / <scp>GIPR</scp> Agonist‐To‐Antagonist Molecule Achieves Superior Weight Loss in Obese Mice2026
  4. 43068-LB: A Next-Generation GLP-1/GIP/GCG/Gastrin Quadruple Agonist with Potent Antiobesity and Glucose-Lowering Effects2026
  5. 5Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders2025 · 1 citations